A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants - Trial NCT06264440
Access comprehensive clinical trial information for NCT06264440 through Pure Global AI's free database. This Phase 1 trial is sponsored by Biogen and is currently Recruitment Completed. The study focuses on Healthy Volunteer. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Biogen
Timeline & Enrollment
Phase 1
Feb 12, 2024
May 07, 2024
Primary Outcome
Maximum Observed Concentration (Cmax) of BIIB122,Area Under the Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration (AUClast) of BIIB122,Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of BIIB122
Summary
The primary objective of the study is to evaluate the effects of a proton pump inhibitor
 (PPI) [rabeprazole] on BIIB122 pharmacokinetics (PK) after a single dose in healthy
 participants. The secondary objective of the study is to evaluate the safety and tolerability
 of BIIB122, with and without a PPI (rabeprazole), after a single dose in healthy
 participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06264440
Non-Device Trial